Adicet Bio reports prula-cel Phase 1 enrollment doubles to 20+ patients; FDA allows outpatient dosing for SLE/LN

Adicet Bio, Inc.

Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.
FDA alignment achieved to allow outpatient dosing of SLE and lupus nephritis patients in ongoing and future trials.
Plans to request FDA meeting in Q2 2026 to discuss potential Phase 2 pivotal trial design for prula-cel.
Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer expected in H1 2026.
Cash runway extended into H2 2027 following $74.8M net proceeds from October 2025 equity offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.